Matches in Wikidata for { <http://www.wikidata.org/entity/Q64695413> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q64695413 description "clinical trial" @default.
- Q64695413 description "ensayu clínicu" @default.
- Q64695413 description "klinisch onderzoek" @default.
- Q64695413 description "клінічне випробування" @default.
- Q64695413 description "կլինիկական փորձարկում" @default.
- Q64695413 name "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection" @default.
- Q64695413 type Item @default.
- Q64695413 label "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection" @default.
- Q64695413 prefLabel "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection" @default.
- Q64695413 P1050 Q64695413-25340823-8CE7-4763-837C-3B48622F0992 @default.
- Q64695413 P1050 Q64695413-2DBAE9C1-2991-4941-821F-E4614DA6AA3A @default.
- Q64695413 P1050 Q64695413-40BAE03D-9EC4-47A1-A696-1BD42D40042A @default.
- Q64695413 P1132 Q64695413-5B998B26-508E-481F-901E-2CBC92CC35A0 @default.
- Q64695413 P1476 Q64695413-96340D6B-130B-44A2-93AD-D918890A5AE2 @default.
- Q64695413 P17 Q64695413-1483682A-FEB5-43D4-8B32-C0930E5A49BE @default.
- Q64695413 P17 Q64695413-42376723-4608-49A0-AEEB-B1C33C44B39D @default.
- Q64695413 P17 Q64695413-4EC9A890-A044-464D-9520-CFAB905BCA2B @default.
- Q64695413 P17 Q64695413-80F14BA6-D8E5-49CA-A817-3BA8A08B3BBD @default.
- Q64695413 P17 Q64695413-9E596EC5-3C44-4550-9299-8DD68CB3D084 @default.
- Q64695413 P17 Q64695413-A9B53BAF-BDDB-47C3-A04F-A93BF0AFB5C1 @default.
- Q64695413 P17 Q64695413-ABA4D533-8735-4036-99F4-23B690CBB520 @default.
- Q64695413 P2899 Q64695413-8059BC88-44C7-46A0-8E29-7413FF7F4246 @default.
- Q64695413 P3098 Q64695413-E08D6F44-735C-4FAD-8D8B-D5123D045DF7 @default.
- Q64695413 P31 Q64695413-DB0BE14E-063A-4371-92BE-FE85DC8BB212 @default.
- Q64695413 P4844 Q64695413-BD8E2003-BB84-4E54-A093-4730601EDB15 @default.
- Q64695413 P580 Q64695413-325ADA9B-B1D2-400A-8597-4D3701EC7F02 @default.
- Q64695413 P582 Q64695413-7A54B60C-8FF5-40B0-9E34-7D08ED438CED @default.
- Q64695413 P6099 Q64695413-09777A96-2B06-4B4B-B3A4-7D497835F902 @default.
- Q64695413 P8363 Q64695413-75976D24-0559-4DCC-B39C-309D5BF9FD57 @default.
- Q64695413 P859 Q64695413-61559F36-0ABB-4ECF-8021-FC7337D316BB @default.
- Q64695413 P1050 Q131742 @default.
- Q64695413 P1050 Q154869 @default.
- Q64695413 P1050 Q157661 @default.
- Q64695413 P1132 "+229" @default.
- Q64695413 P1476 "A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infectio" @default.
- Q64695413 P17 Q142 @default.
- Q64695413 P17 Q16 @default.
- Q64695413 P17 Q183 @default.
- Q64695413 P17 Q30 @default.
- Q64695413 P17 Q38 @default.
- Q64695413 P17 Q40 @default.
- Q64695413 P17 Q408 @default.
- Q64695413 P2899 "+18" @default.
- Q64695413 P3098 "NCT00963885" @default.
- Q64695413 P31 Q30612 @default.
- Q64695413 P4844 Q20817235 @default.
- Q64695413 P580 "2009-08-01T00:00:00Z" @default.
- Q64695413 P582 "2012-01-01T00:00:00Z" @default.
- Q64695413 P6099 Q42824440 @default.
- Q64695413 P8363 Q78089383 @default.
- Q64695413 P859 Q212646 @default.